REVIEW doi: 10.12032/TMRCR20200728016 TMR Clinical Research Meta-analysis of the clinical efficacy and safety of Urinary Kallidinogenase in the treatment of acute cerebral infarction Yuan Qin1, Qian Yi2, Hui-Hui Shi2, Ya-Lin Qi2*, Jing-Yue Hu2 1Chongqing Mental Health Center, Geleshan ward eight ward, Chongqing 400036, China. 2Military Army Medical University (Third Military Medical University) Daping Hospital Neurology, Chongqing 400010, China. *Corresponding to: Ya-Lin Qi. Daping Hospital, Army Medical University (Third Military Medical University. NO. 10, Changjiang branch road, Daping, Yuzhong district, Chongqing 400042, China. E-mail:
[email protected]. Highlights The treatment of cerebral infarction by Urinary Kallidinogenase can improve the neurological defect symptoms, improve the quality of life, and the adverse reaction rate is low, and the safety is good, which provides evidence-based evidence for the treatment of cerebral infarction by Urinary Kallidinogenase. Submit a manuscript: https://www.tmrjournals.com/tcr TMR | November 2020 | vol. 3 | no. 4 | 131 doi: 10.12032/TMRCR20200728016 REVIEW Abstract Objective: To evaluate the clinical efficacy and safety of Urinary Kallidinogenase for Injection in the treatment of acute cerebral infarction. Methods: PubMed, The Cochrane Library, Embase, CNKI, VIP, Wan Fang and bibliographic database of Chinese medicine were searched by computer to collect randomized controlled trials of Urinary Kallidinogenase 's treatment of acute cerebral infarction. The time limit was set up until September 2019. At the same time, the references and grey literature in the literature were manually screened. Two independent researchers were screened, evaluated and extracted according to inclusion and exclusion criteria. Meta-analysis was carried out by RevMan 5.3 software.